Cinqair(Reslizumab Intravenous Infusion)

	授权形式：	免费版	作者/开发商：
	文件大小：	150.3 Kb	解压密码：
	软件语言：	简体中文	更新时间：	2016-07-08
	版本号：	1.0	软件平台：	Win2000/WinXP/Win2003
	软件类别：	国产软件	演示地址：
	评分等级：	★★★★☆	注册地址：
	发布人：	admin	下载次数：	0（今日：0，本周：0，本月：0）
	插件认证：	无插件	浏览次数：	0

本地下载： 下载地址

FDA has approved Cinqair (reslizumab) for use with asthma medicines for the maintenance treatment of severe asthma in patients aged ≥18 years. Cinqair reduces severe asthma by reducing the levels of blood eosinophils, a type of white blood cell that contributes to the development of asthma.
Indications: Cinqair is approved for patients who have a history of severe attacks (exacerbations) despite receiving their current asthma medications.
Dosage/administration: Cinqair is administered once every 4 weeks via intravenous infusion by a health care professional in a clinical setting prepared to manage anaphylaxis. It is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in murine myeloma non-secreting 0 (NSO) cells.
CINQAIR Rx
Add Drug To My List Compare to related Drugs View/edit/Compare drugs in my list
Select the drug indication to add to your list
CINQAIR
Asthma/COPD  Only 4 drugs may be compared at once
Generic Name and Formulations:
Reslizumab 100mg/10mL; soln for IV infusion; preservative-free.
Company:
Teva Pharmaceuticals

Select therapeutic use: Asthma/COPD
Indications for CINQAIR:
As add-on maintenance treatment of severe asthma in patients ≥18yrs old, and with an eosinophilic phenotype.

Limitations Of use:
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.

Adult:
Give by IV infusion over 20–50mins. ≥18yrs: 3mg/kg once every 4 weeks.

Children:
<18yrs: not established.

Warnings/Precautions:
Should be administered by healthcare provider prepared to manage anaphylaxis. Observe patient for a period of time post-infusion; discontinue immediately if severe systemic reactions or anaphylaxis occur. Not for treating acute asthma symptoms or exacerbations. Treat pre-existing helminth infections before initiating therapy; discontinue Cinqair if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt cessation of systemic or inhaled corticosteroids upon Cinqair initiation; reduce dose gradually if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.

Pharmacological Class:
Interleukin-5 antagonist.

Adverse Reactions:
Oropharyngeal pain, elevated CPK, myalgia; anaphylaxis, malignancy.

Generic Availability:
NO

How Supplied:
Single-use vial—1